OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Moore on the Investigation of Nab-sirolimus in TSC1/2-Mutated Gynecologic Cancers and Other Solid Tumors

October 27th 2022

Kathleen N. Moore, MD, MS, discusses the investigation of nab-sirolimus in TSC1/2-mutated gynecologic cancers.

Dr. Rampal on ACVR1 Inhibition With Pacritinib in Myelofibrosis

October 27th 2022

Raajit K. Rampal, MD, PhD, discusses the investigation of ACVR1 inhibition as a mechanism for improving anemia in patients with myelofibrosis.

Women in Oncology: Opportunities for Success Through Mentorship

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the importance of strong mentorship relationships and the unique growth opportunities they found at different points of their careers.

Women in Oncology: Actively Preparing for Advances in Leukemia Treatment

October 27th 2022

Courtney DiNardo, MD, MSCE; Eunice Wang, MD; and Jessica Altman, MD, discuss the toughest challenges they faced in the leukemia field at the start of their fellowships and careers.

Dr. Maziéres on the Evaluation of Tepotinib Plus Osimertinib in EGFR-mutated NSCLC

October 26th 2022

Julien Maziéres, MD, PhD, discusses the evaluation of tepotinib plus osimertinib in EGFR-mutated non–small cell lung cancer.

Dr. Ueno on Patient-Reported Outcomes With Trastuzumab Deruxtecan in HR+/HER2-Low Breast Cancer

October 26th 2022

Naoto T. Ueno, MD, PhD, FACP, discusses patient-reported outcomes with fam-trastuzumab deruxtecan-nxki (Enhertu) in hormone receptor (HR)–positive/HER2-low metastatic breast cancer.

Dr. Cohen on the Use of ctDNA for Chemotherapy Decisions in CRC

October 26th 2022

Stacey A. Cohen, MD, discusses the evaluation of the role of circulating tumor DNA to determine the benefit of chemotherapy in colorectal cancer.

Dr. Garfall of the FDA Approval of Teclistamab in Relapsed/Refractory Multiple Myeloma

October 25th 2022

Alfred L. Garfall, MD, discusses the significance of the FDA approval of teclistamab-cqyv in relapsed/refractory multiple myeloma and how this agent might fit into the treatment paradigm going forward.

Dr. Kalinsky on the Importance of Molecular Profiling in Breast Cancer

October 25th 2022

Kevin Kalinsky, MD, MS, discusses the importance of molecular profiling in breast cancer.

Dr. Borad on the Next Steps for Research Evaluating RLY-4008 in FGFR2+ Cholangiocarcinoma

October 25th 2022

Mitesh Borad, MD, discusses the next steps for investigating RLY-4008 in cholangiocarcinoma harboring FGFR2 fusion or rearrangement.

Dr. DiSilvestro on the Long-Term OS Benefit of Olaparib Maintenance in Ovarian Cancer

October 24th 2022

Paul A. DiSilvestro, MD, discusses the long-term survival benefit of olaparib maintenance in advanced BRCA-mutated ovarian cancer.

Dr. Kuykendall on Treatment Considerations with Ruxolitinib in Myelofibrosis

October 24th 2022

Andrew Kuykendall, MD, discusses treatment considerations with ruxolitinib in myelofibrosis.

Dr. Aragon-Ching on the Future Implications of the JAVELIN Bladder 100 Trial in Urothelial Cancer

October 24th 2022

Jeanny B. Aragon-Ching, MD, FACP, discusses the future implications of the phase 3 JAVELIN Bladder 100 trial in urothelial cancer.

Dr. Stone on the Use of E-selectin as a Target to Overcome Treatment Resistance in AML

October 24th 2022

Richard M. Stone, MD, discusses potential ways to address drug resistance in acute myeloid leukemia by targeting E-selectin.

Dr. Varga on Current Clinical Trials for Patients with Relapsed/Refractory Multiple Myeloma

October 24th 2022

Cindy Varga, MD, discusses several exciting clinical trials at the Levine Cancer Institute for patients with relapsed/refractory multiple myeloma with acquired resistance to BCMA-directed therapy.

Dr. McKenzie on Navigating the Landscape of Biomarker Testing in NSCLC

October 24th 2022

Andrew McKenzie, PhD, discusses the variety of molecular testing modalities in patients with metastatic non–small cell lung cancer.

Dr. Stollenwerk on the Effect of Robotic Bronchoscopy on Lung Cancer Diagnosis

October 24th 2022

Nicholas Stollenwerk, MD, discusses the real-world effects of robotic-assisted bronchoscopy on diagnosis and treatment for patients with lung cancer.

Dr. Schenk on the Effect of Nivolumab Plus Relatlimab in Basal Cell Carcinoma

October 21st 2022

Kara M. Schenk, MD, discusses the effect of nivolumab plus relatlimab in advanced basal cell carcinoma.

Dr. Lipson on the Impact of Preoperative Nivolumab Plus Relatlimab in NSCLC

October 21st 2022

Evan J. Lipson, MD, discusses the effect of preoperative nivolumab plus relatlimab in resectable non-small cell lung cancer (NSCLC).

Dr. Garassino on Updates From the KEYNOTE-189 Trial in NSCLC

October 21st 2022

Marina Chiara Garassino, MD, discusses updates from the phase 3 KEYNOTE-189 trial in non–small cell lung cancer.